人类ABCG2：结构、功能及其在多药耐药中的作用。
Human ABCG2: structure, function, and its role in multidrug resistance.
作者信息
Mo Wei, Zhang Jian-Ting
机构信息
Department of Pharmacology and Toxicology and IU Simon Cancer Center, Indiana University School of Medicine Indianapolis, IN 46202, USA.
出版信息
Int J Biochem Mol Biol. 2012;3(1):1-27. Epub 2011 Mar 30.
Abstract
Human ABCG2 is a member of the ATP-binding cassette (ABC) transporter superfamily and is known to contribute to multidrug resistance (MDR) in cancer chemotherapy. Among ABC transporters that are known to cause MDR, ABCG2 is particularly interesting for its potential role in protecting cancer stem cells and its complex oligomeric structure. Recent studies have also revealed that the biogenesis of ABCG2 could be modulated by small molecule compounds. These modulators, upon binding to ABCG2, accelerate the endocytosis and trafficking to lysosome for degradation and effectively reduce the half-life of ABCG2. Hence, targeting ABCG2 stability could be a new venue for therapeutic discovery to sensitize drug resistant human cancers. In this report, we review recent progress on understanding the structure, function, biogenesis, as well as physiological and pathophysiological functions of ABCG2.
摘要
人类ABCG2是ATP结合盒（ABC）转运蛋白超家族的成员，已知其在癌症化疗中导致多药耐药（MDR）。在已知会导致MDR的ABC转运蛋白中，ABCG2因其在保护癌症干细胞中的潜在作用及其复杂的寡聚结构而特别引人关注。最近的研究还表明，小分子化合物可以调节ABCG2的生物合成。这些调节剂与ABCG2结合后，会加速内吞作用并转运至溶酶体进行降解，从而有效缩短ABCG2的半衰期。因此，靶向ABCG2的稳定性可能是治疗耐药性人类癌症的新治疗靶点。在本报告中，我们综述了关于ABCG2的结构、功能、生物合成以及生理和病理生理功能的最新研究进展。
相似文献
1
Human ABCG2: structure, function, and its role in multidrug resistance.
Int J Biochem Mol Biol. 2012;3(1):1-27. Epub 2011 Mar 30.
2
Reversal of ABCG2-mediated drug resistance by tinodasertib (ETC-206).
Front Pharmacol. 2025 Jun 13;16:1606857. doi: 10.3389/fphar.2025.1606857. eCollection 2025.
3
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
5
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
6
Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters.
bioRxiv. 2025 May 27:2025.05.22.651305. doi: 10.1101/2025.05.22.651305.
8
Relationship Between Pituitary Gland and Stem Cell in the Aspect of Hormone Production and Disease Prevention: A Narrative Review.
Endocr Metab Immune Disord Drug Targets. 2025 Jan 13. doi: 10.2174/0118715303314551241031093717.
9
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
Cochrane Database Syst Rev. 2013 Jan 31(1):CD009593. doi: 10.1002/14651858.CD009593.pub2.
10
Management of urinary stones by experts in stone disease (ESD 2025).
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
引用本文的文献
1
Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma.
J Cell Mol Med. 2025 Aug;29(16):e70816. doi: 10.1111/jcmm.70816.
2
Neisseria meningitidis regulates P-glycoprotein transporter activity in brain endothelial cells via sphingosine 1-phosphate receptor 1.
Fluids Barriers CNS. 2025 Jul 22;22(1):78. doi: 10.1186/s12987-025-00687-0.
3
Elevated BCRP Transporter and Altered NF-кB Pathway Mediate Zoledronic Acid Resistance in MCF-7 Cells.
J Biochem Mol Toxicol. 2025 Jul;39(7):e70397. doi: 10.1002/jbt.70397.
4
Adipose-Derived Stem Cells at the Crossroads of Obesity and Cancer.
Stem Cell Rev Rep. 2025 Jul 3. doi: 10.1007/s12015-025-10918-4.
5
Outcomes Associated With ABCG2 and CD133 Expression in Patients With Gastric Cancer After Surgical Resection.
Korean J Helicobacter Up Gastrointest Res. 2023 Dec;23(4):283-293. doi: 10.7704/kjhugr.2023.0039. Epub 2023 Dec 8.
6
Co-expression of HIF1A with multi-drug transporters (P-GP, MRP1, and BCRP) in chemoresistant breast, colorectal, and ovarian cancer cells.
J Genet Eng Biotechnol. 2025 Jun;23(2):100496. doi: 10.1016/j.jgeb.2025.100496. Epub 2025 May 1.
7
Inhibition of ABCG2 by SCO-101 Enhances Chemotherapy Efficacy in Cancer.
Int J Mol Sci. 2025 Apr 17;26(8):3790. doi: 10.3390/ijms26083790.
8
Reduction in Liver Cancer Risk by Quercetin via Modulation of Urate Levels: Insights from Drug-Target Mendelian Randomization.
Genes (Basel). 2025 Apr 13;16(4):449. doi: 10.3390/genes16040449.
9
PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer.
Invest New Drugs. 2025 Apr;43(2):337-347. doi: 10.1007/s10637-025-01526-7. Epub 2025 Apr 24.
10
Mechanism of microRNA-152-3p-Mediated Regulation of Autophagy and Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells.
Onco Targets Ther. 2025 Feb 4;18:179-197. doi: 10.2147/OTT.S485100. eCollection 2025.
本文引用的文献
1
Different roles of TM5, TM6, and ECL3 in the oligomerization and function of human ABCG2.
Biochemistry. 2012 May 1;51(17):3634-41. doi: 10.1021/bi300301a. Epub 2012 Apr 19.
2
Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistance.
Mol Pharmacol. 2012 Mar;81(3):328-37. doi: 10.1124/mol.111.075556. Epub 2011 Nov 23.
3
Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma.
Oncogene. 2011 Dec 1;30(48):4814-23. doi: 10.1038/onc.2011.189. Epub 2011 May 30.
4
The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2.
J Cell Physiol. 2012 Feb;227(2):729-38. doi: 10.1002/jcp.22781.
5
Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.
J Nucl Med. 2011 Mar;52(3):415-23. doi: 10.2967/jnumed.110.079608. Epub 2011 Feb 14.
6
Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.
Biochem Pharmacol. 2011 Mar 15;81(6):783-92. doi: 10.1016/j.bcp.2010.12.018. Epub 2011 Jan 8.
7
Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1.
Biochem Biophys Res Commun. 2011 Jan 21;404(3):853-8. doi: 10.1016/j.bbrc.2010.12.074. Epub 2010 Dec 22.
8
Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.
PLoS One. 2010 Dec 7;5(12):e15276. doi: 10.1371/journal.pone.0015276.
9
The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.
Drug Metab Dispos. 2011 Mar;39(3):426-32. doi: 10.1124/dmd.110.035212. Epub 2010 Dec 7.
10
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
J Pharmacol Exp Ther. 2011 Jan;336(1):223-33. doi: 10.1124/jpet.110.175034. Epub 2010 Oct 15.
Zotero 插件